Yohei Kawashima

Ageoshimo, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 48 publications

Visualizing Baseline Eligibility Across Locally Advanced or Metastatic Urothelial Cancer Trials and Real-World Cohorts.

Visualizing Baseline Eligibility Across Locally Advanced or Metastatic Urothelial Cancer Trials and Real-World Cohorts.

Journal: International journal of urology : official journal of the Japanese Urological Association

Published: May 11, 2026

Real-world Outcomes of Adjuvant Nivolumab in High-risk Bladder and Upper Tract Urothelial Carcinoma after Radical Surgery.

Real-world Outcomes of Adjuvant Nivolumab in High-risk Bladder and Upper Tract Urothelial Carcinoma after Radical Surgery.

Journal: European urology open science

Published: April 19, 2026

Visualizing eligibility gaps between muscle-invasive bladder cancer trials and real-world patients.

Visualizing eligibility gaps between muscle-invasive bladder cancer trials and real-world patients.

Journal: Japanese journal of clinical oncology

Published: March 24, 2026

Association of EVITA with safety in advanced urothelial carcinoma: A multicenter real-world study.

Association of EVITA with safety in advanced urothelial carcinoma: A multicenter real-world study.

Journal: Urologic oncology

Published: February 16, 2026

Fully Extraperitoneal Robotic Sacrohysteropexy Compared With Transperitoneal Robotic Sacrocervicopexy for Anterior and Apical Pelvic Organ Prolapse.

Fully Extraperitoneal Robotic Sacrohysteropexy Compared With Transperitoneal Robotic Sacrocervicopexy for Anterior and Apical Pelvic Organ Prolapse.

Journal: International journal of urology : official journal of the Japanese Urological Association

Published: January 05, 2026

Efficacy, Safety, and Cost-Effectiveness of Reduced versus Full Initial Doses of Androgen Receptor Signaling Inhibitors in Non-Metastatic Castration-Resistant Prostate Cancer: A Multicenter Retrospective Study.

Efficacy, Safety, and Cost-Effectiveness of Reduced versus Full Initial Doses of Androgen Receptor Signaling Inhibitors in Non-Metastatic Castration-Resistant Prostate Cancer: A Multicenter Retrospective Study.

Journal: The Prostate

Published: December 31, 2025

Presenting postoperative mortality as percentages and natural frequencies (1-in-N) in major urologic cancer surgeries.

Presenting postoperative mortality as percentages and natural frequencies (1-in-N) in major urologic cancer surgeries.

Journal: Urologic oncology

Published: December 27, 2025

Association of Prophylactic Intravenous Corticosteroid Premedication With Toxicity and Survival in Patients Receiving Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma.

Association of Prophylactic Intravenous Corticosteroid Premedication With Toxicity and Survival in Patients Receiving Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma.

Journal: International journal of urology : official journal of the Japanese Urological Association

Published: November 17, 2025

Deferred Cytoreductive Nephrectomy in Unresectable/Metastatic Renal Cell Carcinoma: A Real-World Multicenter Retrospective Study.

Deferred Cytoreductive Nephrectomy in Unresectable/Metastatic Renal Cell Carcinoma: A Real-World Multicenter Retrospective Study.

Journal: International journal of urology : official journal of the Japanese Urological Association

Published: October 14, 2025

Cross-resistance among novel androgen receptor signaling inhibitors in non-metastatic castration-resistant prostate cancer.

Cross-resistance among novel androgen receptor signaling inhibitors in non-metastatic castration-resistant prostate cancer.

Journal: International journal of clinical oncology

Published: June 20, 2025

Real-world trends in the use and outcomes of novel androgen receptor signaling inhibitor therapy in patients with non-metastatic castration-resistant prostate cancer: a multicenter retrospective study.

Real-world trends in the use and outcomes of novel androgen receptor signaling inhibitor therapy in patients with non-metastatic castration-resistant prostate cancer: a multicenter retrospective study.

Journal: International journal of clinical oncology

Published: April 13, 2025

Efficacy of modified enfortumab vedotin ineligible criteria (mEVITA) in advanced urothelial carcinoma.

Efficacy of modified enfortumab vedotin ineligible criteria (mEVITA) in advanced urothelial carcinoma.

Journal: Scientific reports

Published: March 10, 2025

Showing 1-12 of 48

Last Updated: 09/26/2026